BIOMAT Database Logo BIOMAT Database Logo

Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase. 1989

K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Factor IX BM Nagoya (IX Nagoya) is a natural mutant of factor IX responsible for severe hemophilia B. A patient with this mutant is characterized by a markedly prolonged ox brain prothrombin time. IX Nagoya was purified from the patient's plasma by immunoaffinity chromatography with an anti-factor IX monoclonal antibody column. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed that treatment of IX Nagoya with factor XIa/Ca2+ resulted in cleavage only at the Arg145-Ala146 bond. Reversed-phase high performance liquid chromatography of a trypsin digest of IX Nagoya showed an aberrant peptide, which was further digested with proteinase Asp-N. Primary structure analysis of one of the Asp-N peptides revealed that Arg180 is replaced by Trp. An essentially complete (99%) amino acid sequence of IX Nagoya was obtained by sequencing fragments derived from a lysyl endopeptidase digest in which no other substitutions in the catalytic triad or substrate binding site were found. We also found that IX Nagoya is activated by alpha-chymotrypsin or rat mast cell chymase by monitoring the rate of factor X activation using a fluorogenic peptide substrate in the presence of factor VIII, phospholipids, and Ca2+. These results indicate that the substitution of Arg180 by Trp impairs the cleavage by factor XIa required for activation of this zymogen and that the substitution causes hemophilia BM.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008407 Mast Cells Granulated cells that are found in almost all tissues, most abundantly in the skin and the gastrointestinal tract. Like the BASOPHILS, mast cells contain large amounts of HISTAMINE and HEPARIN. Unlike basophils, mast cells normally remain in the tissues and do not circulate in the blood. Mast cells, derived from the bone marrow stem cells, are regulated by the STEM CELL FACTOR. Basophils, Tissue,Basophil, Tissue,Cell, Mast,Cells, Mast,Mast Cell,Tissue Basophil,Tissue Basophils
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010449 Peptide Mapping Analysis of PEPTIDES that are generated from the digestion or fragmentation of a protein or mixture of PROTEINS, by ELECTROPHORESIS; CHROMATOGRAPHY; or MASS SPECTROMETRY. The resulting peptide fingerprints are analyzed for a variety of purposes including the identification of the proteins in a sample, GENETIC POLYMORPHISMS, patterns of gene expression, and patterns diagnostic for diseases. Fingerprints, Peptide,Peptide Fingerprinting,Protein Fingerprinting,Fingerprints, Protein,Fingerprint, Peptide,Fingerprint, Protein,Fingerprinting, Peptide,Fingerprinting, Protein,Mapping, Peptide,Peptide Fingerprint,Peptide Fingerprints,Protein Fingerprint,Protein Fingerprints
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002918 Chymotrypsin A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side. Alpha-Chymotrypsin Choay,Alphacutanée,Avazyme
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005164 Factor IX Storage-stable blood coagulation factor acting in the intrinsic pathway of blood coagulation. Its activated form, IXa, forms a complex with factor VIII and calcium on platelet factor 3 to activate factor X to Xa. Deficiency of factor IX results in HEMOPHILIA B (Christmas Disease). Autoprothrombin II,Christmas Factor,Coagulation Factor IX,Plasma Thromboplastin Component,Blood Coagulation Factor IX,Factor 9,Factor IX Complex,Factor IX Fraction,Factor Nine,Factor IX, Coagulation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
November 1990, Thrombosis research,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
June 1986, Thrombosis research,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
May 1989, Journal of biochemistry,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
December 1988, Journal of biochemistry,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Defective propeptide processing of blood clotting factor IX caused by mutation of arginine to glutamine at position -4.
May 1986, Cell,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Factor IX Cardiff: a variant factor IX protein that shows abnormal activation is caused by an arginine to cysteine substitution at position 145.
August 1989, British journal of haematology,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Activation of rat serosal mast cells by chymase, an endogenous secretory granule protease.
May 1984, Journal of immunology (Baltimore, Md. : 1950),
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Inhibitors of chymase as mast cell-stabilizing agents: contribution of chymase in the activation of human mast cells.
November 1999, The Journal of pharmacology and experimental therapeutics,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
The interaction of bovine factor IX, its activation intermediate, factor IX alpha, and its activation products, factor IXa alpha and factor IXa beta, with acidic phospholipid vesicles of various compositions.
June 1986, The Biochemical journal,
K Suehiro, and S Kawabata, and T Miyata, and H Takeya, and J Takamatsu, and K Ogata, and T Kamiya, and H Saito, and Y Niho, and S Iwanaga
Activated mast cells induce endothelial cell apoptosis by a combined action of chymase and tumor necrosis factor-alpha.
February 2008, Arteriosclerosis, thrombosis, and vascular biology,
Copied contents to your clipboard!